Secondary hematological malignancies associated with temozolomide in patients with glioma

Abstract

Despite the limitations of this study, published reports and our results suggest that TMZ induces secondary hematological malignancies, particularly ALL, and might shorten the latency period when used in combination with other chemotherapeutic agents.